How To Improve Blood Flow

describe systemic (and/or local) application of omentum-derived lipid fractions or the use of their bio- or organic-synthetic or purified analogs for the acceleration of vascularization, neovascularization, vascular collateralization, promotion of perfusion, and collagen formation or scarring and organization (cellular and collagenous) of myocardiac ischemic lesions.

The effect of bFGF on collateral blood flow in dogs subjected to ameroid-induced occlusion of the left circumflex coronary artery (LCX). , to immediately improve circulation and thus avoid further damage to the heart. A method according to claim 1, wherein the growth promoting peptide is administered continuously apple customer privacy statement over hours or days at such a rate as to obtain the desired daily effective dosage amount. An even more preferred method comprises injecting 110 μg of bFGF per injection, which injection is made once per day on the days that injections are administered. A method according to claim 1, wherein said growth promoting peptide is career job search australia in the form of a solution, which is administered as a slow bolus, which comprises about two ml of the solution comprising said growth promoting peptide, over a two minute period of time followed by a one ml saline flush. The patient's heart muscle is usually weakened permanently, to some degree by such scar tissue.
In addition to the above treatments for a MI, current practice also includes preventative measures. The above data related to the Franco patent could not have related to the growth of blood vessels to treat a heart attack for additional reasons. 18, 1988 to Catsimpoolas et al, relates to treating the heart with angiogenesis healing factors. There is no technology in existence at the present time that can foster the in vivo growth of new blood vessels in the heart, thereby improving cardiac blood flow. In accordance with the invention there is also disclosed a method of treating atherosclerosis of the coronary arteries by improving cardiac blood flow via the growth of cardiac blood vessels in a mammal, while reducing the risk of undesired vascularization in other areas of the body, comprising: (a) inserting a catheter into a coronary artery and providing an infusion port of said catheter accessible to the administration of coronary drug injections; (b) injecting an effective amount into the heart of a blood vessel growth promoting peptide through said infusion port of said catheter; and (c) repeating periodically on subsequent days the step of injecting said blood vessel growth factor via said catheter, with said periodic injections being continued until improved cardiac blood flow has been obtained. The method for increasing cardiac blood flow according to the present invention has particular advantages since it overcomes the problems in the art related to problems of increased vascularation in undesired areas. "Effects of Acidic Fibroblast Growth Factor on Normal and Ischemic Myocardium", Banai et al.
Further, the peptides might be expected to be readily broken down by the digestive system if administered by an oral route. Recombinant DNA vector encoding human endothelial cell growth factor4911717March, 1990Gaskill, III623/11Intravasular artificial organ5021044June, 1991Sharkawy604/53Catheter for even distribution of therapeutic fluids5026839June, 1991Moscatelli et al. One method involves improving cardiac blood flow by surgically bypassing diseased vessels (coronary artery bypass surgery).

By way of example of the invention method, disclosed below are specific experimental data relating to the growth of cardiac blood vessels in dogs which clearly prove the utility of the present process.

Further preferred truck spare part man is a method as described above wherein the periodic injections are continued for about 2 to 8 weeks and the solutions of the active ingredient are administered in a period of about 10 seconds to about 10 hours, for example, administered as a slow bolus of about 2 ml over 2 minutes followed by a 1 ml saline flush.

Another method for mechanically improving cardiac blood flow by opening the existing diseased vessels is called percutaneous transluminal coronary angioplasty (PTCA).
This direct injection into the heart or intravenous injection is preferred.

(See, for example, Banai et al. The infusion port of the catheter was secured in the subcutaneous tissues of the left lateral abdominal wall, establishing access for intracoronary drug injections. Any one of the above mechanisms or a combination of them may cause a MI. , 10 seconds, to many hours, e. A method according to claim 9, wherein the basic fibroblast growth factor is administered in an amount of about 75-300 μg per injection. Method for treatment of angina and myocardial infarctions with omental lipids4868113September, 1989Jaye et al. BACKGROUND ART The seriousness and prevalence of heart disease is well known to people in the medical arts. The other two methods cause damage to the artery, and the healing response of the artery to this injury often causes the buildup of a type of scar tissue which itself causes significant obstruction of the vessel. DESCRIPTION OF THE INVENTION The phrase "repeating periodically on subsequent days," as used both above and below in describing the present invention, is defined as continuing the step of injecting the peptide into the heart at more than one time on the same day, if necessary, and on additional designated days. Heart attacks, or myocardial infarction (MI) may be described as ischemic necrosis that is due to partially or completely blocked coronary arteries in the heart which starves the heart muscle for nutrients and oxygen. A method according to claim 12, wherein the collateral myocardial blood flow can be quantified during chromonar-induced glow in the dark mini put maximum vasal dilation and expressed as an ischemic/normal zone ratio represented by the formula ratio IZ/NZ.

on line legal help Myocardial blood flow was determined with microspheres three days after ameroid placement and weekly for 5 weeks thereafter. WO/1991/013649September, 1991DILATATION CATHETER Lang Medical Publications, Los Angeles, Calif. 4,296,100, issued to Franco on Oct. (Rockville, MD) Images are available in PDF form when logged in. During the first months following a heart attack the overall mortality rate is about 30%, with most deaths occurring in the first 24 to 48 hours. A thoracotomy was performed in the left fifth intercostal space using sterile techniques.

A method according to claim 6, wherein said vascular endothelial growth factor is administered in an amount of about 25-200 μg per injection. Also preferred is a method wherein the VEGF is administered in an amount of half moon bay brewery about 20-500 μg per injection, preferably about 25-200 μg.
applications 07/389722 (filed Aug. The pericardium and chest were closed in layers and the dogs were allowed to recover. : Effects of acidic fibroblast growth factor on normal and ischemic myuocardium, Circulation Research 69, pages 76-85 (1991)). During the last six years, a number of proteins have been characterized that promote the growth of blood vessels in vitro. A method according to claim 1 further comprising the step of determining the rate and sufficiency of miocardia blood flow by microspheres after the placement of the catheter and prior to treatment; and subsequently determining the rate and sufficiency of blood flow on a weekly basis during the course of treatment. Examples of such growth factors or their bioactive fragments are epidermal growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, vascular endothelial cell growth factor, and the like.

A particularly preferred embodiment of the present invention is a method wherein the blood vessel growth promoting peptides used for injecting into the heart to stimulate cardiac blood vessel growth are independently selected from the group consisting of vascular completely free ring tone endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF), a growth promoting bioactive peptide fragment of vascular endothelial growth factor, a growth promoting bioactive peptide fragment of basic fibroblast growth factor, or a mixture of said peptides. Drugs are sometimes given to prevent platelet aggregation and avoid recurrent MIs for several months following the heart attack.
To remedy these blocked arteries and to avoid deprivation causing scar tissue to the heart, physicians have used mechanical methods to improve the cardiac blood flow. Accordingly, the present invention provides a method as described above and, preferably, further provides a method also comprising the step of determining the rate and sufficiency of miocardial blood flow by microspheres after the placement of the catheter and prior to treatment; and subsequently determining the rate and sufficiency of blood flow on a weekly basis during the course of treatment. Further, it is possible to produce analogs of such peptides having single or multiple amino acid substitutions, deletions, additions, or replacements.

Injections of vascular endothelial growth hormone (VEGF) 45 μg (N=9), basic fibroblast growth factor (bFGF) 110 μg (N=9), or placebo (N-12) were made on a daily basis (Monday through Friday). As noted above, the effective amounts of the peptide administered and the frequency required for injections will vary depending upon the activity of the particular peptide.
All such allelic variations, modifications, and analogs resulting in derivatives with retain the biologically active properties of native or synthetic known growth promoting peptides as described above are included within the scope of the present invention. In the first hours after infarction, streptokinase or tissue plasminogen activator (tPa) can dissolve blood clots in coronary arteries, restoring blood flow to the heart muscle and avoiding infarction. The peptide injected may be a single peptide or a mixture of peptides. A method according to claim 6, wherein the vascular endothelial growth factor is injected at about 45 μg per injection, which injection is made once per day on the days that injections are administered. Thus, the method, frequency of injections, and the peptide injected may be varied and adapted to meet the treatment needs of a particular patient. Instead, this patent relates to treatment with omentum-derived lipid fractions, for example, from cat omentum. The endothelial cell growth factor may be obtained as disclosed, for example, in U. Also, the basic fibroblast growth factor may be obtained as described, for example, in U.

Such an approach is needed that can potentially partially or completely replace blocked coronary arteries with new blood vessels without affecting the degree of vascularity in the area of the body. In order to rehabilitate patients, gradual return to work and increases in exercise are generally prescribed.

Surprisingly, the present inventors have discovered that the above method will promote improved cardiac circulation via the generation of new blood vessels in the heart and will avoid or minimize the undesired side effects such as increased vascularization in undesired other areas.
For this purpose β-adrenergic blocking drugs are also sometimes administered.

Current treatment will sometimes include reopening a severe blockage by balloon catheters or similar devices (angioplasty), or use of bypass surgery. To view PDFs, Loginor View patents that cite this patent Click for automatic bibliography generation 604/53, 604/890. Ten days after the operation, the dogs were randomized to receive one of two peptides or a placebo. Solutions were given as a slow bolus (2 ml over 2 minutes) followed by 1 ml saline flush. It is another object of the present invention to provide a procedure or method by which peptides may be made operable in vivo to promote new cardiac blood vessel growth in mature cardiac tissue, when such peptides have only been previously characterized or shown to promote the growth of blood vessels in vitro or in embryonic tissue. - Previous Patent (Suction irrigator en. When the deprivation of oxygen and nutrients is severe, the tissue dies and is replaced by scar tissue which is not useful as heart muscle. These injections described by consumer energy in michigan Franco collectively concern a one-time treatment immediately following a myocardial infarction (injections are given during one 24 hour period of time) This treatment is given as close to the time the heart attack as possible in order to control damage, i. 4, 1989) and 07/351,117 (filed May 12, 1989), which were published as providing the priority theme vista window xp for Australian Patent application 9056574 (published Nov. Any of the peptides listed above or others that may be shown to have similar tissue growth stimulating functionality, either in vitro or in embryonic tissue, may be used in the above method. The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept and therefore such adaptations are intended to be comprehended within the meaning and range of equivalents of a disclosed embodiment.
A series of spaced injections (different locations in the heart) are used to distribute the desired amount of FGF over the area of the heart to be treated. Despite their great promise in the treatment of cardiovascular disease, none have been successfully utilized in vivo to date. In accordance with this invention there is disclosed a method to facilitate in a damaged heart or a heart in need of improved circulation the growth of cardiac blood vessels while reducing the risk of undesired vascularization in other areas of the body comprising: (a) inserting a catheter into a coronary artery and providing an infusion port of said catheter accessible to the administration of coronary drug injections; (b) injecting an effective amount into the heart of a blood vessel growth promoting peptide through said infusion port of said catheter; and (c) repeating periodically on subsequent days the step of injecting said blood vessel growth factor via said boston ma calendar of event catheter, with said periodic injections being continued until improved cardiac blood flow has been obtained. Blood flow was quantified on a weekly basis.
A vein is usually used for the bypass.
This american social welfare policy was regarded as surprising since lipid materials are often considered to be atherosclerotic agents which cause MIs rather than preventing them.

Further, some reliable data has been published recently in a peer-reviewed journal which indicates that application of fibroblast growth factor in the context of infarction may actually be dentrimental to the patient.
TECHNICAL FIELD The present invention relates to improvements in the treatment of diseases, and more particularly to procedures and compositions used to foster myocardial blood vessel growth and improve blood flow to the heart. The amount of peptide injected or the number of injections on a given day may then be varied to obtain the desired level of increase in cardiac circulation. Another temporary measure for treating the heart soon after a myocardial infarction is described in U. Collateral flow can be quantified during Chromonar-induced maximum vasodilation and expressed as an ischemic/normal zone (IZ/NZ) ratio.
It is a further object of financial aid for single moms the present invention to provide an improved method of treating atherosclerosis of the coronary arteries by improving cardiac blood flow by treatment with peptides that promote blood vessel growth. Another preferred method comprises administering bFGF in an amount of about 50-700 μg, preferably about 75-300 μg. The periods of administration of the growth factor in the method according to the invention can range from a period of a few seconds, e.

08 in the treated and control groups, respectively (p 0. The damaged vascular or myocardial system is not rebuilt. )Next Patent (Infusion pump with o.

However, subcutaneous, intramuscular and oral injection is also described.
The invention may be applied to a method for treating atherosclerosis of the coronary arteries, which comprise as part of the x man mugen character treatment steps the above method for improving cardiac blood flow via the growth of cardiac blood vessels. It is to be understood that the phraseology or terminology employed herein is for the purposes of description only and not of limitation. , 10 hours, contiuous administration over hours or days might also be a beneficial treatment regimen and is within the scope of the present invention. EXAMPLE 1 The process of the invention was used to facilitate the growth of cardiac blood vessels in dogs. BRIEF DESCRIPTION OF THE DRAWINGS FIG. This method involves inflation of a balloon inside the blood vessel at the blockage point to crack and compress the atherosclerotic material outward, hence april birthstone ringapril bowlby enlarging the diameter of the vessel. A silastic catheter was inserted proximal to the ligature and advanced retrogradely until the end was positioned at the takeoff of the marginal branch from the LCX (see FIG.
These growth factors or bioactive fragments are known to influence cellular growth, differentiation and migration.
This involves open heart surgery where a blood vessel is taken from some other part of the body and attached to the blocked artery both in front of the blockage and beyond of it in order to bypass the obstruction and cause the blood flow to go around the blockage. Collateral flow was quantified during chromonar-induced maximal vasodilation and expressed as an ischemic/normal zone (IC/NZ) ratio. A method according to claim 1, wherein said growth promoting peptide is in the form of a solution, which is administered, over a period of 10 seconds to about 10 hours. SUMMARY OF THE INVENTION It is an object of the present invention to overcome the difficulties in the prior art as set forth in the background to the invention.

In this balloon surgery, a stent a stint (a device to keep the walls of the artery from collapsing back upon themselves) may be inserted at the blockage point. After two weeks of treatment the IZ/NZ ratio in bFGF treated dogs surpassed that of control dogs; final IZ/NZ blood flow ratios were 0. Again, the underlying damaged myocardial vasculature is not altered by this mode of treatment.